Novartis, Shire issue pink slips

Share this article:

Vivus is just one of a slate of companies that recently announced they were reducing workforce. The Boston Globe reports that Novartis has added 500 pink slips to that pile, pulling jobs from a research program in California, while at the same time opening 175 positions in Cambridge, MA. The Globe notes that Cambridge's gain somewhat offsets the recent announcement that Vertex was releasing employees, due to a hazardous HCV sales environment.

Shire is also cutting jobs. Reuters reports the specialty drugmaker is cutting around 180 R&D jobs at its Basingstoke, UK, office, where it has 520 people on-staff. The streamlining is part of the company's “One Shire” initiative.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.